Dantrolene has 9 known drug interactions based on U.S. FDA drug labeling data. Of these, 3 are contraindicated combinations that should be avoided entirely. 1 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Calcium Channel Blockers, Verapamil, Verapamil Hydrochloride. Patients taking Dantrolene should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 9
- Contraindicated
- 3
- Major
- 1
- Moderate
- 4
Contraindicated (3)
- Dantrolene + Calcium Channel Blockers— Cardiovascular collapse in association with marked hyperkalemia reported; intravenous dantrolene not recommended with ca…
- Dantrolene + Verapamil— Cardiovascular collapse and marked hyperkalemia reported with IV dantrolene and calcium channel blockers; contraindicate…
- Dantrolene + Verapamil Hydrochloride— Animal studies suggest concomitant intravenous use of verapamil and dantrolene sodium may result in cardiovascular colla…
Major (1)
- Dantrolene + Vecuronium— Dantrolene may potentiate vecuronium-induced neuromuscular blockade.
Moderate (4)
- Dantrolene + Carbamazepine— CYP3A4 inhibitor that increases carbamazepine plasma levels; close monitoring and dosage adjustment may be required.
- Dantrolene + Clofibrate— Clofibrate reduces binding of dantrolene to plasma proteins, potentially increasing free drug concentration.
- Dantrolene + Tolbutamide— Tolbutamide increases binding of dantrolene to plasma proteins, potentially decreasing free drug concentration.
- Dantrolene + Warfarin— Warfarin reduces binding of dantrolene to plasma proteins, potentially increasing free drug concentration.